Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlers.
Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Kawade A, Lalwani S, Ravi MD, Ramanan PV, Kamath V, Agarwal A, Dogar V, Gautam M, Jaganathan KS, Kumar R, Sharma I, Gairola S. Sharma H, et al. Among authors: ravi md. Vaccine. 2024 Dec 2;42(26):126380. doi: 10.1016/j.vaccine.2024.126380. Epub 2024 Sep 19. Vaccine. 2024. PMID: 39303376 Free article. Clinical Trial.
Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
Matur RV, Thuluva S, Gunneri S, Yerroju V, Reddy Mogulla R, Thammireddy K, Paliwal P, Mahantshetty NS, Ravi MD, Prashanth S, Verma S, Narayan JP. Matur RV, et al. Among authors: ravi md. Vaccine. 2024 May 10;42(13):3157-3165. doi: 10.1016/j.vaccine.2024.03.056. Epub 2024 Apr 17. Vaccine. 2024. PMID: 38637211 Clinical Trial.
A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL®) in infants.
Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Kawade A, Lalwani S, Ravi MD, Kamath V, Mahopatra J, Kulkarni G, Tayade D, Ramanan PV, Uttam KG, Rawal L, Gawande A, Kumar NR, Tiple N, Vagha J, Thakkar P, Khandgave P, Deshmukh BJ, Agarwal A, Dogar V, Gautam M, Jaganathan KS, Kumar R, Sharma I, Gairola S. Sharma H, et al. Among authors: ravi md. NPJ Vaccines. 2024 Feb 22;9(1):41. doi: 10.1038/s41541-024-00828-w. NPJ Vaccines. 2024. PMID: 38383584 Free PMC article.
Immunogenicity and safety of HavisureTM vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study.
Susarla SK, Gupta M, Uttam KG, Palkar S, Dhongade AR, Siva Ram Prasad K, Rajapantula V, Ravi MD, Pradeep N, Satish M, Rajashakar BC, Sandhya G, Rajendra L, Sahoo DP, Kanakasapapathy AK. Susarla SK, et al. Among authors: ravi md. Vaccine. 2023 Oct 6;41(42):6215-6220. doi: 10.1016/j.vaccine.2023.08.084. Epub 2023 Sep 1. Vaccine. 2023. PMID: 37661535 Clinical Trial.
COVID-19 vaccine triggered autoimmune hepatitis: case report.
Mathew M, John SB, Sebastian J, Ravi MD. Mathew M, et al. Among authors: ravi md. Eur J Hosp Pharm. 2023 Dec 27;31(1):82-83. doi: 10.1136/ejhpharm-2022-003597. Eur J Hosp Pharm. 2023. PMID: 37591684 Free PMC article. No abstract available.
COVID-19 vaccine triggered autoimmune hepatitis: case report.
Mathew M, John SB, Sebastian J, Ravi MD. Mathew M, et al. Among authors: ravi md. Eur J Hosp Pharm. 2023 Sep;30(5):e27. doi: 10.1136/ejhpharm-2022-003485. Epub 2022 Oct 7. Eur J Hosp Pharm. 2023. PMID: 36207131 Free PMC article.
Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study.
Mangarule S, Prashanth S, Kawade A, Ravi MD, Padmavathi IV, Palkar S, Tripathi VN, Singh R, Maurya M, Mitra M, Shetty RS, Kompithra RZ, Dhaded SM, Epari V, Moureau A, Jayanth MV, Varghese K, Ravinuthala S, Kukian D, Patnaik BN, Noriega F. Mangarule S, et al. Among authors: ravi md. Vaccine X. 2022 Sep 13;12:100216. doi: 10.1016/j.jvacx.2022.100216. eCollection 2022 Dec. Vaccine X. 2022. PMID: 36164460 Free PMC article.
Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12-24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in India.
Mangarule S, Palkar S, Mitra M, Ravi MD, Singh R, Moureau A, Jayanth MV, Patel DM, Ravinuthala S, Patnaik BN, Jordanov E, Noriega F. Mangarule S, et al. Among authors: ravi md. Vaccine X. 2022 Jul 2;11:100190. doi: 10.1016/j.jvacx.2022.100190. eCollection 2022 Aug. Vaccine X. 2022. PMID: 35899104 Free PMC article.
31 results